CTAD24 | Clinical Trials on Alzheimer's Disease

Madrid, Spain | 29 October - 1 November 2024

Be the first to gain access to new data and insights, presented at CTAD24.

This year at CTAD, we can’t wait to share our latest research with you. There will be four posters, with Michael Spilka, PhD taking us through his research in a Oral Communications session.

Thursday 31st October, 10:10am for 10:25am presentation

OC21 Validating speech-based biomarkers for measuring disease progression in AD: A head-to-head comparison of three biomarker development strategies.

How can automated analysis of patient speech can provide an objective, low-burden, and patient-relevant measure of clinical progression in Alzheimer’s disease to complement traditional endpoints in AD clinical trials?

Poster Session 3: Friday 1st November, 7:15am – 5:00pm

LP093 Comparability and Usability of Cambridge Neuropsychological Test Automated Battery (CANTAB®) tests delivered via a smartphone. Emily Thorp
Is there comparability between smartphone and desktop devices used at home on Bring your own device (BYOD), and can norms and other associated measures be relevant to the smartphone format?

P179 Longitudinal analysis of the factor structure of a multidomain cognitive task battery in ageing and preclinical AD. Nick Taptiklis

P183 Exploring Novel RT-Based Measures Calculated from Detailed Paired Associate Learning Task Data: Preliminary Analyses. Alex Kaula Phd, presented by Nick Taptiklis

Don’t miss out on being the first to access the latest posters by registering your interest below. As soon as we are able to share these with you, we will send them directly to your inbox!